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Rate adaptation of the action potential ensures spatial heterogeneities in conduction across the 
myocardium are minimised at different heart rates providing a protective mechanism against 
ventricular fibrillation (VF) and sudden cardiac death (SCD), which can be quantified by the 
Ventricular Conduction Stability (V-CoS) test previously described. We tested the hypothesis 
that patients with a history of aborted SCD due to an underlying channelopathy or 
cardiomyopathy have a reduced capacity to maintain uniform activation following exercise.  
Methods 
60 individuals, with (n=28) and without (n=32) previous aborted-SCD event underwent ECGi 
recordings following exercise treadmill test. These included 25 Brugada Syndrome, 13 
Hypertrophic Cardiomyopathy, 12 idiopathic VF and 10 healthy controls. Data was inputted 
into the V-CoS programme to calculate a V-CoS score that indicate the percentage of 
ventricle that showed no significant change in ventricular activation, with a lower score 
indicating the development of greater conduction heterogeneity.  
Results: 
The SCD group, compared to those without, had a lower median (interquartile range) V-CoS 
score at peak exertion (92.8%(89.8-96.3%) vs 97.3%(94.9-99.1%); p<0.01) and 2 minutes 
into recovery (95.2%(91.1-97.2%) vs (98.9%(96.9-99.5%); p<0.01). No significant 
difference was observable later into recovery at 5 or 10 minutes. Using the lowest median V-
CoS scores obtained during the entire recovery period post exertion, SCD survivors had a 
significantly lower score than those without for each of the different underlying aetiologies.  
Conclusion:  
Data from this pilot study demonstrate the potential use of this technique in risk stratification 
for the inherited cardiac conditions. 
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Condensed abstract  
We assess a novel method to rapidly quantify the degree of conduction heterogeneity that 
may develop in those with an impaired rate adaptive response. Data from this pilot study 
demonstrate the potential use of this technique in risk stratification for the inherited cardiac 
conditions regardless of underlying cause 
 
What’s new 
• Survivors of aborted sudden cardiac arrest develop greater spatial heterogeneities in conduction 
and repolarisation than those without following modulation in autonomic tone and heart rate. 
• We assess the V-CoS test in its ability to discriminate between individual at high risk and low 
risk of future ventricular arrhythmias in a range of of Inherited Cardiac Conditions 
• The V-CoS test detects abnormalities in cardiac conduction following exercise and has the 















Arrhythmogenicity in the inherited cardiac conditions (ICCs) begins with the inheritance or 
spontaneous acquisition of one or several genetic mutations. These consequentially translate 
into channelopathies or cardiomyopathies that impair the propagation and physiological rate 
adaptive responses of the action potential, affecting the recovery of excitability across the 
ventricles which predict ventricular fibrillation. 1-4 This may be further modulated by heart 
rate or changes in autonomic tone which have previously been observed to play a critical role 
in the development of arrhythmias in the ICCs. 5-8  
 
We developed and described the V-CoS test previously as a method to quantify the 
alterations in whole heart activation patterns following exercise in-vivo.9 We previously 
demonstrated the utility of this test as a potential marker of risk, although it remained unclear 
if this could be applied as an adjunctive discriminator for the different ICCs and those with an 
idiopathic cause of VF. In this study, we validate the V-CoS test in a larger cohort of patients 
with different ICCs and test the hypothesis that SCD survivors, irrespective of the underlying 
genetic abnormality, have an abnormal rate adaptive response resulting in greater spatial 
heterogeneities in conduction developing following exertion than those without a previous 




For this study, patients with and without a previous aborted sudden cardiac death (SCD) or 
equivalent event with different ICCs were recruited. Patients meeting criteria for a diagnosis 
of Brugada Syndrome (BrS), Hypertrophic Cardiomyopathy (HCM) or an idiopathic cause 
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ventricular fibrillation/tachycardia (iVF/VT) were identified and enrolled.7 Patients with 
structurally normal hearts with no history of syncope or family history of sudden death/ICC 
undergoing electrophysiological studies and required ECGi mapping for ventricular ectopy or 
supra-ventricular arrhythmias were also studied as a control group. Individuals with an 
aborted SCD or equivalent event were defined as those requiring resuscitation following a 
cardiac arrest or an appropriate shock from their ICD.  
 
Study protocol 
Enrolled patients had the non-invasive electro-cardiographic imaging (ECGi) vest fitted and 
secured, before undergoing exercise treadmill and a non-contrast CT chest on the same day. 
The Bruce protocol was employed and stopped when maximal exertion was achieved. This 
was defined as reaching and sustaining maximum target heart rate adjusted for age, or 
cessation owing to fatigue after achieving a minimum of 85% of their maximum target heart 
rate. Patients were immediately returned to the supine position where ECGi recordings were 
then performed over a 10 minute recovery period, to eliminate interference, movement and 
motion artefact. Subjects were excluded from analysis if they were unable to perform or 
complete exercise treadmill test protocol on the day of ECGi recording. The study protocol 
was reviewed and approved by the National Research Ethics Committee - London 
(ref:14/LO/1318). 
 
The body surface electrogram and reconstructed unipolar epicardial electrogram (EGM) 
signal data obtained over this period was subsequently extracted from the ECGi system and 
analysed with the V-CoS programme (Figure 1). The torso, ventricles, tricuspid and mitral 
valve and left anterior descending artery geometry were also segmented from the cardiac CT 
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scan using the EcVUE user interface within the ECGi system software. Data encoding the 
torso and ventricular shell, valves and coronary arteries was also extracted and processed 
with the V-CoS programme. 
 
ECGI and Signal Processing with the V-CoS test 
The EcVUE system (Medtronic Inc, USA) was used for ECGi processing. This involved 
body surface potential data obtained via a 252-electrode vest which was combined with 
patient specific heart-torso geometry derived from a thoracic CT scan (Figure 1 & 
Supplemental Figure 1). Using inverse solution mathematical algorithms, the ECGi system 
reconstructed epicardial unipolar electrograms and panoramic activation maps over a single 
sinus beat which were visualised on a digitised image of the patient’s heart on EcVUE system 
user interface. 
 
The V-CoS programme has been described in detail previously. 9 Briefly, the programme 
allows the rapid and automated comparison of ventricular electrogram data and activation 
patterns between two different beats – one from a reference phase (e.g. resting baseline) and 
the other from a test phase (e.g. peak exertion). Differences in local activation timings 
between the two phases were calculated for every electrogram with a spatial point over the 
heart surface or mesh created by the ECGi system (fuller description under supplementary 
methods). 
 
To provide a measure of conduction stability, or a surrogate measure of an appropriate rate 
adaptive response, a V-CoS score was automatically derived. This indicated the percentage of 
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epicardial electrograms across the ventricular surface where no significant changes in local 
activation timing (less than 10ms) occurred between the reference and test phases. A higher 
percentage or score denoted greater conduction stability or a normal rate adaptive 
mechanism. Examples of reconstructed ECGi activation and V-CoS maps for each sub-group 
of study patients are shown in supplemental figure 2. 
 
Data analysis 
Electrograms were analysed at peak exertion (defined as within a minute of cessation of 
exercise), and during recovery at 2 minutes, 5 minutes and 10 minutes. Calculation of V-CoS 
scores were determined with reference to the end of the 10-minute recovery period and were 
based on detecting differences or changes in local activation timing (LAT) at each point on 
the ventricular surface that was in excess of 10 milliseconds as previously described. 
 
Receiver Operating Characteristic (ROC) analysis and graphs were calculated to assess the 
diagnostic performance of the V-CoS test, with the area under the curve expressed as the C-
statistic. This was based on the minimum V-CoS score achieved by each individual at all test 
phases. The Youden index, defined as sensitivity+specificity-1.00, was then calculated for all 
points on the ROC curve.10 The maximum value of the index was used as the criterion for 
selecting a cut-off point or threshold to denote optimal sensitivity and specificity.  
 
Assessment of SCD risk with conventional risk stratification techniques  
In patients with BrS, a prior history of syncope and the presence of a spontaneous Type I BrS 
pattern as defined previously was ascertained at enrolment16, or before the SCD event in 
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survivors to ascertain the predictive value of these risk markers. Individuals were then 
grouped into three categories according to the presence these factors. High risk – denoting the 
presence of both syncope and spontaneous type I pattern; Intermediate risk – the presence of 
either syncope or spontaneous type I pattern; Low risk – the absence of either. 
 
For patients with HCM, the ESC 5 year SCD risk score was calculated for each individual.11 
This was performed retrospectively in study patients 16 years or older based on data obtained 
on initial evaluation. To assess the ESC risk score’s predictive value in those who first 
presented with an aborted SCD event to our institute, a prior history of syncope was 
considered present if occurred before their presenting SCD event. All other clinical 
parameters were obtained based on subsequent work up. High risk individuals were deemed 
as those having a 5 year risk of >6%; Intermediate risk – 4 to 6%; Low risk - <4%.12  
 
Statistical analysis 
Normality testing was performed using the D'Agostino-Pearson test. For non-normally 
distributed variables, the Kruskal-Wallis test (or Friedman’s test for repeated measures) was 
used for comparison of three of more groups. For post hoc analysis, the Mann-Whitney test 
was employed for comparison between two groups with Dunn’s correction where multiple 
comparisons were required. Statistical analysis was performed using GraphPad PRISM v5 
(Graphpad Software Inc, USA), and a p value of <0.05 was considered significant.  
 
Results 
Study group characteristics  
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The V-CoS test was applied to 28 patients with a previously aborted SCD event (mean age 
40±11 years, 24 males) and 32 patients without a previous SCD event (mean age 44±12 
years, 21 males) who underwent exercise treadmill testing with the ECGi vest. The SCD 
group comprised of 12 patients with an idiopathic cause of sustained VF/VT, 10 with BrS and 
6 with HCM. In the non-SCD group, 15 BrS patients, 7 HCM patients and 10 control patients 
with structurally normal hearts. A summary of clinical characteristics of these different 
subgroups are summarised in supplemental tables 1-4. In 3 patients (with previous aborted 
SCD), anti-arrhythmic therapy was not discontinued prior to the study protocol for clinical 
reasons.   
 
SCD vs non-SCD group 
Following peak exertion in both groups, a gradual increase in V-CoS scores (median 
(interquartile range)) could be observed over the 10 minute recovery period (NSCD group: 
97.3% (94.9-99.1%) to 99.8% (99.1-100%), p<0.001; SCD group: 92.8% (89.8-96.3%) to 
99.8% (98.7-100%), p<0.001) (Figure 2). In the early recovery period, V-CoS scores were 
observed to be significantly lower in the SCD than non-SCD group immediately following 
peak exertion (92.8% (89.8-96.3%) vs 97.3% (94.9-99.1%), p=0.03) and at 2 minutes (95.2% 
(91.1-97.2%) vs 98.9% (96.9-99.5%), p<0.01). No significant differences between the groups 
could be observed by 5 minutes and 10 minutes into recovery (Table 1). There were no 
significant differences in heart rate between groups at each stage of recovery (Table 1).  
 
V-CoS scoring within the different subgroups 
Sub-group analysis was also performed between SCD and non-SCD patients according to 
underlying aetiology. A similar pattern of recovery of V-CoS scores in SCD and non-SCD 
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patients could be observed in all three subgroups:- i) iVF/VT vs controls ii) BrS-SCD vs BrS 
iii) HCM-SCD vs HCM (Figure 3 & Supplemental Figure 3). 
 
Those with previous aborted SCD events were found to have a lower V-CoS score than non-
SCD patients in the early stages of recovery for all three subgroups. In the first subgroup, 
iVF/VT survivors had lower median scores than controls following peak exertion (94.2% vs 
96.8%, p=0.06) with a significant difference on recovery at 2 minutes (96.3% vs 98.8%, 
p=0.006). No significant differences were observed at 5 and 10 minutes. In the BrS group, a 
significant difference between SCD and non-SCD patients was also observed immediately 
following peak exertion (92.3% vs 95.1%, p=0.009) and at 2 minutes post-recovery (91.3% 
vs 97.8%, p=0.001) but not at the other stages. In the HCM group, a significant difference 
between the SCD and non-SCD patients was only observed following peak exertion (93.4% 
vs 99.3, p=0.0047). 
 
As the time point during recovery at which conduction abnormalities occurred could have 
varied for the different ICCs and between individuals, we analysed the lowest V-CoS scores 
obtained throughout the whole recovery period for each person and pooled their scores 
according to their sub-groups (Figure 4 & Supplemental Figure 4). The median minimal V-
CoS scores post exertion were found to be significantly lower in patients with a previously 
aborted SCD event than those without for all three subgroups (iVF vs controls: 94.2% vs 
96.5%, p=0.03) (BrS SCD vs BrS: 90.9% vs 94.5%, p=0.004) (HCM SCD vs HCM: 93.4% 
vs 99.2%, p=0.004). Although the differences were statistically significant, it was observed 
that there was a degree of overlap between the iVF subjects and controls (supplemental 
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figure 4), highlighting the likely heterogeneity in the electrophysiological substrate of the 
iVF group. 
 
Predictive performance of V-CoS and comparison to current risk stratification 
Area under the ROC curve (C-statistic) was 0.82 (standard error ±0.05) when applied to all 
patients in this study. The C-statistic ranged from 0.79-0.93 when it was applied to each of 
the different subgroups as shown in Figure 5. Based on the Youden index, a cut-off 
minimum V-CoS score at 93.9% provided a sensitivity and specificity of 87.5% and 67.9% 
respectively when applied to all patients. In the BrS group, a cut off minimum score at 92.3% 
derived from Youden index, provided a sensitivity and specificity of 80.0% and 86.7% 
respectively. In HCM, a threshold at 97.0% provided a sensitivity and specificity at 100% 
and 85.7% respectively. A Youden index derived threshold of 96.4% in iVF/VT provided a 
sensitivity and specificity of 83.3% and 70.0% respectively.  
 
As an exploratory study of the small subgroups of BrS and HCM patients, V-CoS testing was 
compared to conventional markers or risk. In the BrS cohort, conventional risk stratification 
based on the presence of a spontaneous Type I BrS pattern and syncope identified 2 out of 10 
(20%) of the patients with aborted SCD events as high risk. Most of these patients would 
have been identified as low risk given the absence of these parameters. With V-CoS testing, a 
threshold of 92.3% identified 80% of the SCD cohort as high risk (Figure 6). In the HCM 
sub-group, the C-statistic for the V-CoS test (0.95) was 0.14 higher than C-statistic of the 
ESC risk score calculator (0.81). Using the threshold of 97%, the V-CoS test correctly 





In this study, the V-CoS test was applied to a larger cohort of patients with ICC with previous 
aborted SCD events, who demonstrated a significantly lower V-CoS score than those without 
SCD events following an exertional stress test. Interestingly, the same pattern was observed 
for each of the different inherited cardiac condition subgroups enrolled in this study. This 
supports the hypothesis that increased spatial changes in activation between phases is 
associated with increased arrhythmogenic potential regardless of the underlying aetiology.  
 
Previous clinical studies in BrS and HCM patients have demonstrated the existence of spatial 
heterogeneities in conduction 13-15, and increase in arrhythmogenic potential following 
exertion.8,16-19 In iVF patients, Peeters and colleagues had previously described the finding of 
late potentials on SAECG in such a cohort, suggesting the presence of regions with slow 
conduction to support re-entrant arrhythmias.20 Saumarez et al had also found that local 
electrograms were wider and more fractionated after pacing at shorter coupling intervals in 
patients with iVF when compared to unaffected controls, suggesting that intraventricular 
conduction delay has a role in the arrhythmogenic mechanism in these patients.4 Whether the 
development of spatial heterogeneities in conduction are related purely to the effects of heart 
rate and/or autonomic modulation is currently unclear and will require further investigation. 
 
A degree of similarity or V-CoS score overlap could also be observed between the controls 
and BrS/HCM individuals without previous aborted SCD events (supplemental figures 3 
and 4). This would be in keeping with the notion that absence of significant conduction delay 
or the development of spatial heterogeneities in conduction would be at lower risk of 
developing re-entrant ventricular arrhythmias even in the presence of an inherited cardiac 
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condition. It was of interest to observe that individuals with HCM (without previous aborted 
SCD) had similar and overlapping scores to low risk individuals without structural heart 
disease. We postulate that this may relate to the degree of underlying fibrosis present and its 
correlation with VCoS scores will require further investigation. 
 
As a measure of arrhythmogenic potential, the minimum V-CoS score was considered as the 
pattern of V-CoS recovery appeared to differ between groups. In the iVF and HCM groups 
the lowest V-CoS scores could be primarily observed just after peak exertion in comparison 
to that seen in the BrS group where a lowered V-CoS score could be observed at 2 minutes in 
recovery. This variation in arrhythmogenic potential is in keeping with clinical conservation 
and reports of ventricular arrhythmias occurring during peak exertion rather than recovery in 
HCM, and on early recovery of post exertion in BrS.16,17,19  
 
Based on the Youden’s index employed in the analysis of the ROC curves, there appeared to 
be different thresholds or cut-offs to indicate the optimal sensitivity and specificity of the V-
CoS test. Whilst the interpretation of this is limited by the relatively small numbers in each 
group, it would suggest that having a common threshold applied to all the different 
pathologies may dilute the sensitivity/specificity of the test. The effect of this will need to be 
evaluated in a larger cohort of patients.  
 
The use of conventional surface ECG and ECGi electrophysiological parameters has been 
previously explored in a group of patients that form part of this study cohort, where SCD 
survivors possessed the greatest amount of dispersion of repolarisation and regional 
conduction abnormalities following exertion.8 It would stand to reason that the lowest V-CoS 
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scores found in SCD survivors are the result of these electrophysiological perturbations 
detected by conventional means. As to what degree repolarisation abnormalities may also be 
reflected by this score or the additive effect of other ECGi electrophysiological parameters 
remains to be investigated. 
 
In comparison to conventional risk stratification techniques for BrS and HCM, V-CoS testing 
would appear to have greater accuracy to identify individuals at high risk of SCD. In those 
with idiopathic VF/VT, there is an absence of a formal apriori risk stratification system. In 
one of our patients with iVF, an ICD had been implanted for primary prevention following a 
multidisciplinary discussion at our institute. This was made on the basis of ongoing 
intermittent palpitations, a family history of SCD and having a similar ECG of T wave 
inversion in the inferior leads to her deceased brother. All other investigations were normal 
(including Holter, exercise ECG and MRI). Three years later, she received an appropriate 
shock for VF from her device with no other apparent cardiac abnormality on subsequent 




Given the small numbers within each subgroup, a prospective study involving a much larger 
group of patients is required to validate these findings before this may be translated into 
clinical management.  
Factors such as gender and age may affect sensitivity/specificity of the test although numbers 
in this study are too small to allow meaningful analysis. Although no significant differences 
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were observed between comparative study groups, the effects of such factors on the 
sensitivity and specificity of V-CoS testing will be need to be explored in future studies.  
We assume ECGi provides a reasonable reflection of epicardial activation patterns based on 
previous validation work of the system, but also acknowledge the limitations in its 
reconstructive accuracy.9 As we are quantifying magnitude of change within an individual 
using the same heart-torso geometry data and have algorithms in place to resolve annotation 
issues that can arise as described previosuly,9 we believe these factors are less of an issue. 
We have not tested whether low V-CoS scores observed in the SCD group might be the result 
of a previous episode of VF or defibrillation. However, this would be unlikely because some 
patients within the aborted SCD group have relative high V-CoS scores.  
V-CoS is described as intended to address only timings of activation. We do not know to 
what extent it is associated with repolarisation abnormalities. Direct measures of 
repolarisation may further discriminate those at high risk.  
There is beat to beat variability in measurements which could impair the diagnostic ability of 
V-CoS. However, in a previous study this variability appeared to be small9.  
Finally autonomic tone can be variable and the reproducibility of this test on a different day is 
unknown. We acknowledge that the aforementioned factors may theoretically compound 
variability in measurements of V-CoS scores and requires further study. Whilst this could be 
explored in future, it would require double radiation because each day’s vest positioning 
would need its own CT thorax. In summary, these results and the non-invasive nature of the 
test have important implications for risk stratification but require a large prospective study to 





This study demonstrates the potential discriminative ability of the V-CoS test and its 
application in different types of ICC patients as a tool to measure the electrophysiological 
substrate that predisposes to ventricular fibrillation. The V-CoS test described provides a 
novel approach to automatically quantify alterations in whole heart activation patterns which 
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Figure 1 – Body surface potential data are obtained from the EcVue 252 electrode vest and 
are combined with heart torso geometry obtained from patient’s CT thorax (i-iv). ECGi 
reconstructs >1200 unipolar electrograms over the cardiac surface and 3D activation maps of 
beats obtained at peak exertion and the reference baseline following exercise treadmill testing 
(v). Electrogram data are inputted into the V-CoS programme that produces a score (0-100%) 
to indicate the development of spatial heterogeneities in conduction (vi). 
Figure 2 - Median and interquartile V-CoS scores following exertion in SCD and non-SCD 
groups 
Figure 3 – Trend of V-CoS scores post exertion in SCD and non-SCD patients in the different 
subgroups of patients i) idiopathic ventricular fibrillation/tachycardia (iVF/VT) ii) Brugada 
Syndrome (BrS) iii) Hypertrophic Cardiomyopathy (HCM). Median and interquartile ranges 
values are shown. * p<0.05, ** p<0.01, *** p<0.001. 
Figure 4 – Comparison of minimum V-CoS scores obtained post exertion between SCD and 
non-SCD patients in the different subgroups. Median and interquartile ranges values are 
shown. * p<0.05, ** p<0.01, *** p<0.001. 
Figure 5 – Receiver operating characteristics (ROC) curves showing the predictive 
performance of the V-CoS test when applied to a) all patients b) iVF/VT and structurally 
normal hearts c) Brugada Syndrome and d) Hypertrophic Cardiomyopathy. 
Figure 6 – Comparison of VCoS with conventional risk stratification for BrS  
















































































































V-CoS scores    
Peak Exertion 97.3% (94.9-99.1%) 92.8% (89.8-96.3%) P<0.05 
Recovery 2 
minutes 
98.9% (96.9-99.5%) 95.2% (91.1-97.2%) P<0.01 
Recovery 5 
minutes 
99.5% (97.8-99.8%) 98.4% (95.8-99.3%) P=ns 
Recovery 10 
minutes 
99.8% (99.1-100%) 99.8% (98.7-100%) P=ns 
Heart rate    
Peak Exertion 137 (120-153) 138 (129-155) P=ns 
Recovery 2 
minutes 
94 (88-108) 101 (90-112) P=ns 
Recovery 5 
minutes 
90 (80-99) 91 (84-96) P=ns 
Recovery 10 
minutes 
88 (78-95) 87 (83-98) P=ns 
Table 1 - Summary of median (interquartile range) V-CoS scores and heart rate at each stage 
of recovery post exertion. *Dunn’s multiple comparison test was applied. ns - not significant. 
 
